ML-SA1

ML-SA1 (Mucolipin synthetic agonist 1) is an activator of TRPML channels. ML-SA1 also inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 values of ML-SA1 against DENV2 RNA and ZIKV RNA are 8.93 μM and 52.99 μM, respectively. ML-SA1 induces autophagy. ML-SA1 can be used for the research of broad-spectrum antiviral.

ML-SA1, as a potent inhibitors of DENV2 and ZIKV, can inhibit DENV2 and ZIKV by promoting lysosome acidification and protease activity to cause viral degradation.^{<a class="sref" href="#s_ref">[2]</a>}

Administration of ML-SA1 before transient global ischemia ameliorated neurological dysfunction possibly through the promotion of autophagy and the inhibition of apoptosis.^{<a class="sref" href="#s_ref">[3]</a>}

• Cell lines

  A549 cells, Huh7 cells

• Concentrations

  25 μM

• Incubation Time

  0-14 h

• Method

  A549 or Huh7 cells are seeded into 96-well plates at a density of 8 × 10³ for 12 h, followed by incubation with various concentrations of eML-SA1. After 48 h of incubation, the cell are used for CCK-8 assay. A549 or Huh7 cells are seeded into 12-well plates at a density of 2 × 105 for 12 h and pretreated with 25 μM ML-SA1 for 24 h using DMSO as a control. Then, cells are incubated with 1 μM Lyso-Sensor Green DND-189 for 1 h at 37℃ and digested with 0.25% trypsin to generate a single cell suspension, which is used for Flow Cytometer to investigate the effect of ML-SA1 on lysosomal acidification.

• Animal Models

  Transient global ischemia model mice (male; C57BL/6)

• Dosages

  0.3 μl/min

• Administration

  i.c.